Bio Aurum Works Towards Strengthening IP Portfolio; Files Patent for Early Diagnosis of Alzheimer’s Disease

Bio Aurum has filed a first patent application for an interactive gaze analysis kit for the early diagnosis of neurodegenerative diseases, which is intended to provide early detection of Alzheimer’s disease.

This invention has been developed via the Bio Aurum inventors’ past work on retinal disease, allowing the use of this uniquely observable CNS tissue, with many cellular and functional markers, in a diagnostic method for the early detection of Alzheimer’s disease (AD).

Pathogenic processes in AD can begin as much as a decade before symptoms appear. Early diagnosis can confer critical benefits, such as management of life-style factors that contribute to disease development, access to innovative treatments, potentially more efficacious response to early-stage treatment, and time for patients and families to better plan and manage through the course of the disease.

“There is a strong consensus in the medical and research community regarding the important benefits early diagnosis of neurodegenerative diseases would grant to patients and their families,” commented Dr. Filippo Surace, Co-founder and Executive Chairman of Bio Aurum. “We believe the combination of strong science and strong IP protection will enable us to expand our opportunities and execute on our business model to deliver innovative technologies to the global market.

A further International (PCT) patent filing is planned for 2022, with potential patent expiry in 2042.